敲低Anillin肌动蛋白结合蛋白可阻断小鼠肝细胞胞质分裂并减少肝肿瘤发生而不影响肝再生
该研究在小鼠肝癌模型中敲低ANLN(Anillin肌动蛋白结合蛋白),发现可阻断肝细胞胞质分裂、抑制肝肿瘤发生并延长LAP-MYC小鼠生存时间,且不影响急慢性肝损伤后的肝再生;人肝癌组织中ANLN信使RNA水平高于非肿瘤肝组织。
要点
- 人肝癌组织中ANLN信使RNA水平高于非肿瘤肝组织。
- 敲低ANLN可阻断H2.35肝细胞胞质分裂并抑制小鼠肝肿瘤发生。
- 敲低ANLN不影响急性与慢性肝损伤后的肝再生。
核心结论
- 敲低肝细胞ANLN可阻断胞质分裂并抑制小鼠肝肿瘤发生,作者认为抑制ANLN的药物可能用于肝细胞癌的预防或治疗。
研究设计与样本
- 研究分析癌症基因组图谱、Oncomine、PrognoScan及肝细胞癌组织芯片的临床与基因表达数据。
- 用小干扰RNA在H2.35肝细胞中敲低ANLN并进行胞质分裂图像分析。
- 用脂质纳米颗粒将小干扰RNA递送至发生肝母细胞瘤的LAP-MYC小鼠。
- 将敲低ANLN或对照的H2.35细胞注入发生慢性肝损伤的FRG小鼠并监测肿瘤生长。
- 构建可诱导表达抗Anln信使RNA短发夹RNA的转基因小鼠,在二乙基亚硝胺与四氯化碳处理后研究肝肿瘤发生。
主要发现
- 人肝细胞癌组织中ANLN信使RNA水平高于非肿瘤肝组织。
- 小干扰RNA敲低ANLN可阻断H2.35肝细胞胞质分裂。
- 给予抗ANLN小干扰RNA的LAP-MYC小鼠生存时间较对照小干扰RNA小鼠延长。
- 敲低ANLN的H2.35细胞在FRG小鼠中成瘤速度慢于对照H2.35细胞。
- 可诱导表达抗Anln短发夹RNA的小鼠在二乙基亚硝胺与四氯化碳处理后肝肿瘤数量少于对照小鼠。
关键数值与推荐
- 敲低ANLN不影响急性与慢性肝损伤后的肝再生。
- 原文未报告具体的效应量、置信区间、P值或样本量。
临床怎么用
- 作者认为抑制ANLN的药物可能对肝细胞癌的预防或治疗有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Cytokinesis can fail during normal postnatal liver development, leading to polyploid hepatocytes. We investigated whether inhibiting cytokinesis in the liver slows tumor growth without compromising the health of normal hepatocytes. We inhibited cytokinesis in cancer cells by knocking down ANLN, a cytoskeletal scaffolding protein that regulates cytokinesis and might promote tumorigenesis, in mice with liver disease. METHODS: We analyzed clinical and gene expression data from The Cancer Genome Atlas, Oncomine, PrognoScan, and a hepatocellular carcinoma (HCC) tissue microarray. We knocked down ANLN with small interfering RNAs (siRNAs) in H2.35 liver cells and performed image analyses of cells undergoing cytokinesis. siRNAs were delivered to LAP-MYC mice, which develop hepatoblastoma, using lipid nanoparticles. H2.35 cells with knockdown of ANLN or control cells were injected into FRG mice, which develop chronic liver damage, and tumor growth was monitored. We also developed mice with inducible expression of transgenes encoding small hairpin RNAs (shRNAs) against Anln messenger RNA and studied liver tumorigenesis after administration of diethylnitrosamine and carbon tetrachloride. siRNAs against Anln messenger RNA were conjugated to N-acetylgalactosamine to reduce toxicity and increase hepatocyte tropism; their effects were studied in mouse models of liver cancer and regeneration. RESULTS: Levels of ANLN messenger RNA were increased in human HCC tissues compared to non-tumor liver tissues. siRNA knockdown of ANLN blocked cytokinesis in H2.35 liver cells. Administration of siRNA against ANLN increased survival times of LAP-MYC mice, compared to mice given a control siRNA. H2.35 liver cells with shRNA knockdown of ANLN formed tumors more slowly in FRG mice than control H2.35 cells. Mice with inducible expression of shRNAs against Anln mRNA developed fewer liver tumors after administration of diethylnitrosamine and carbon tetrachloride than control mice. Knockdown of ANLN did not affect liver regeneration after acute and chronic liver injuries. CONCLUSIONS: Knockdown of ANLN in liver cells blocks cytokinesis and inhibits development of liver tumors in mice. Agents that inhibit ANLN in the liver might be effective for prevention or treatment of HCC.
引用
- Zhang S, Nguyen LH, Zhou K, et al. Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration. Gastroenterology. 2017. PMID: 29274368. doi:10.1053/j.gastro.2017.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。